Kornimate/medical-research-clean huggingface dataset:
inspiratory muscle training in patients with acute myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: pneumonia is uncommon high among patients with acute myocardial infarction (ami), which increases adverse clinical events and prolongs the hospital stay. inspiratory muscle training (imt) is able to improve inspiratory muscle strength and prevent pneumonia in patients undergoing cardiac surgery including coronary artery bypass grafting. thus, the investigators design the study mainly aim to evaluate the 30 days imt for the change of inspiratory muscle strength, and also to observe its potentially effect on reducing pneumonia, in participants who accepted primary percutaneous coronary intervention (pci) and at a high risk of pneumonia.

this is a single center, prospective, randomized controlled study. all participants will be followed up until 30 days after randomized.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years, patients with ami undergoing primary pci, admitted to cardiac intensive care unit and at a high pneumonia risk \[2 or more of the following parameters are regarded as high risk for pneumonia: 1. age \> 55 years, 2. diabetes mellitus, 3. smoking at present, 4. chronic kidney disease: estimated glomerular filtration rate \< 60 ml/min/1.73m2, 5. forced expiratory volume in the first second of expiration (fev1) \< 80% predicted and fev1/forced vital capacity (fvc) \< 70% predicted\] * be able to understand and agree with informed consent exclusion criteria: * a history of cerebrovascular accident * treat with immunosuppressive medication for 30 days before * neuromuscular disorder * cardiovascular instability (such as aortic dissection or unstable hemodynamics) * a history of coronary artery bypass grafting (cabg) * expected survival is less than 6 months due to noncardiogenic disease * participated in other drugs and devices studies within 30 days * confirmed as ventricular aneurysm * other conditions not suit for the study after the discussion among the researchers (eg: poor compliance, unable to cooperate for the training)
transseptal needle versus radiofrequency energy for left atrial access

Conditions: Heart Diseases

Summary: this is a randomized controlled trial examining whether a mechanical needle versus a needle that uses radiofrequency energy is better at puncturing through a thin wall in the heart (called "transseptal puncture") as measured by procedure time, during an electrical procedure/study of the heart .

transseptal puncture is a commonly performed procedure allowing access to the left atrium for catheter ablation. historically, a conventional brockenbrough needle has been used for this procedure to mechanically puncture the fossa ovalis, which has been well described in the literature.1, 2 although generally safe, serious complications such as perforation of the atrial wall or aorta can occur.3, 4 previous studies have evaluated the feasibility and safety of radiofrequency (rf) energy applied to a conventional needle as a technique to access the left atrium, particularly in patients with a repeat procedure, fibrotic septum or aneurysmal septum.5, 6 as a result of this earlier work, a special proprietary device has been designed. the nrg rf needle (baylis medical inc., montreal, canada), uses radiofrequency energy emitted from the needle tip to aid in transseptal access. despite limited literature to support its superiority and safety7-9compared to the conventional approach, the new device has become adopted in some electrophysiology procedures involving a transseptal puncture.

Eligibility criteria:
inclusion criteria: * patients undergoing radiofrequency ablation within the left atrium through a transseptal approach * patients greater than 18 years of age exclusion criteria: * patients unable to grant informed, written consent

Keywords: transseptal puncture radiofrequency energy left atrium access left atrial catheterization ablation transseptal catheterization electrocautery catheter ablation atrial fibrillation
p-akt expression on clinical outcomes in malignant lymphoma

Conditions: Malignant Lymphoma; P13K-AKT Pathway Deregulation

Summary: pi3k(phosphatidylinositol 3-kinase)/akt pathway is an important oncogenic signaling pathway. however, clinical information about the significance of p-akt expression in malignant lymphoma is not fully understood yet. in this study, we investigated the overexpression of p-akt and its prognostic implication in malignant lymphoma.

recently, among diverse oncogenic signaling pathways, a number of studies have focused on the significance of oncogenic pi3k/akt (phophatidylinositol 3-kinase/serine-threonine kinase, also known as protein kinase b \[pkb\]) pathway. pi3k(phosphatidylinositol 3-kinase)/akt pathway phosphorylates and activates akt as phosphorylated akt (p-akt) and plays a critical role promoting malignant phenotype and has prognostic significance in various solid cancers. however, a systematic approach on the impact of p-akt overexpression on clinical outcomes has not been performed in malignant lymphoma.

Eligibility criteria:
inclusion criteria: 1. the patients were pathologically confirmed of malignant lymphoma, according to the world health organization classification; 2. the patients had adequate paraffin-embedded biopsy specimen or unstained slides for immunostaining of p-akt. exclusion criteria: 1. primary central nervous system lymphoma was excluded in this study
"treatment use of ecmo in pregnancy or peripartum patient."

Conditions: Cardiogenic Shock; Peripartum Cardiomyopathy; Complication, Pregnancy

Summary: the goal of this study is to describe the use of ecmo (extracorporeal membrane oxygenation) in the pregnant or peripartum patient.


Eligibility criteria:
inclusion criteria: 1. female 2. age 18 years or greater at the time of ecmo treatment. 3. pregnant or within 6 months post-partum at the time of ecmo cannulation exclusion criteria: 1. no history of pregnancy. 2. no treatment with ecmo.
cerebral microembolism in cardiology

Conditions: Cerebral Embolism

Summary: during different interventional cardiology procedures we aim to identify cerebral microemboli load. further we aim to differentiate the quality and the quantity of cerebral microemboli.we will measure cerebral microemboli in different interventional phases, e.g. during valve deployment, rapid pacing, post-implantation.


Eligibility criteria:
inclusion criteria: * age \> 18 years * interventional cardiology procedure (tavi, mitraclip, tricuspidalclip) exclusion criteria: * allergy to ultrasound gel or materials contained in the tcd probe * missing temporal bone window
registry of laypeople's cpr performance

Conditions: Quality of Cardio-pulmonary Resuscitation

Summary: the aim of the registry is to collect laypeople's performance after a bls/aed course carried out with the use of feedback devices.

the registry collect all the laypeople's performance of 1-minute of chest-compression only cpr registered at the end of a cpr/aed course in which feedback devices were used for at least 1 minute. all centers which carry out bls/aed course for laypeople using cpr feedback devices can join to the registry. all the centers have to declare the duration of the course, the guidelines followed, the participants' anthropometric variables and the feedback device they used for the course and for the test. the centers must send the performances of all the participants of a course.

Eligibility criteria:
inclusion criteria: * layperson * participating in a bls/aed course carried out with feedback devices exclusion criteria: * healthcare personnel

Keywords: cardio-pulmonary resuscitation cardiac arrest training
a study of bortezomib, cyclophosphamide, and dexamethasone in patients with untreated multiple myeloma and planned for a high dose chemotherapy

Conditions: Multiple Myeloma

Summary: the purpose of this study is to evaluate the safety and effectiveness of bortezomib in combination with a standard regimen of cyclophosphamide and dexamethasone.

this is open-label (both the participant and the investigator know what treatment participants will receive), prospective (participants are identified and then followed forward in time for the outcome of the study), multi-centre, and non-randomized (participants are assigned to different treatment groups by the investigator) study. the study will be conducted into 2 parts (part 1 and part 2). approximately 400 participants will be enrolled (30 in part 1 and 370 in part 2). in part 1 the optimum dose of cyclophosphamide will be evaluated and in part 2 the selected dose of cyclophosphamide from part 1 will be administered. part 2 will include a screening period of a maximum of 14 days followed by chemotherapy (bortezomib, cyclophosphamide, and dexamethasone) of a maximum of three 21-day cycles. safety will be evaluated by the assessment of adverse events, vital signs, physical examination, electrocardiogram, and clinical laboratory tests which will be monitored throughout the study.

Eligibility criteria:
inclusion criteria: * cytologically or histologically diagnosed with multiple myeloma stage ii/iii * participants without preceding cytostatic (tending to retard cellular activity and multiplication) treatment (pretreatment with radiation or dexamethasone is allowed) * agree to use one of the contraception methods as defined in the protocol * karnofsky performance status 60 percent or more * adequate laboratory test values exclusion criteria: * non-secretory multiple myeloma * estimated life expectancy less than 3 months * history of cancer (except basal cell carcinoma) in the last 5 years * peripheral neuropathy (disorder of the peripheral nerves) grade 2 or more * positive human immunodeficiency virus test and active hepatitis b and/or hepatitis c * pregnant or breast-feeding female participants

Keywords: multiple myeloma untreated multiple myeloma bortezomib velcade cyclophosphamide dexamethasone chemotherapy remission therapy induction therapy stem cell transplantation
a study to continue the administration of deucravacitinib in participants with systemic lupus erythematosus (sle) or discoid and/or subacute cutaneous lupus erythematosus (dle/scle) who have completed study im011074 or study im011132

Conditions: Systemic Lupus Erythematosus (SLE); Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

Summary: the purpose of this study is to allow the continued administration of deucravacitinib in participants with systemic lupus erythematosus (sle) or discoid and/or subacute cutaneous lupus erythematosus (dle/scle) who have completed study im011074 or study im011132


Eligibility criteria:
inclusion criteria * participants must have completed study im011074 or study im011132 through the protocol-required treatment period. * participants must be, based on the physician's medical judgement, likely to receive benefit from receiving treatment with deucravacitinib. * participants must have received ip within 60 days of enrollment. exceptions may be granted based upon consultation with bms. exclusion criteria * participants must not have any disease or medical condition that, in the opinion of the physician, would make the subject unsuitable for this protocol, would interfere with the interpretation of subject safety or considered unsuitable by the physician for any other reason. * participants must not have any evidence of active tuberculosis (tb). * other protocol-defined inclusion/exclusion criteria apply.
impact of continuous veno-venous hemodiafiltration on efficacy of administration of prophylactic doses of enoxaparin or fondaparinux in critically ill patients.

Conditions: Assessment of Activity of Anti-Xa Factor in Patients Treated With Continuous Veno-venous Hemodiafiltration Receiving Anticoagulant Prophylaxis

Summary: dose of anticoagulant prophylaxis in patients with continuous veno-venous hemodiafiltration may be insufficient to keep anti-xa factor activity in prophylactic range.

coagulation disorders are one of the most common complications in critically ill patients. among them deep vein thrombosis and pulmonary embolism are the most significant factors increasing morbidity and mortality in icu patients. use of anticoagulant prophylaxis aims to prevent these dangerous complications. most commonly used anticoagulant prophylaxis agents are low molecular weight heparins (lmwh). lmwh therapeutic efficiency is measured with activity of anti-xa factor, that should range between 0.2 and 0.4 iu/ml in order to prevent thrombotic complications. due to grave general condition, critically ill patients may often develop acute kidney injury (aki), that requires renal replacement therapy (rrt). because of haemodynamic instability the safest therapeutic choice seems to be continuous veno-venous hemodiafiltration (cvvhdf). this rrt mode removes particles in the size of few daltons even up to 10 kilodaltons (kda) such as metabolic product waste, ions, hormones etc. lmwh with average molecular weight of 4.5 kda and fondaparinux with average molecular weight of 1.7 kda may be removed during cvvhdf resulting in insufficient activity of anti-xa factor thus increasing the risk of thrombotic complications in critically ill patients.

Eligibility criteria:
inclusion criteria: * all adult intensive care unit patients between 18 and 80 years old requiring treatment with cvvhdf; * indications for anticoagulant prophylaxis with enoxaparin 40 mg sc. once daily or fondaparinux 2.5 mg sc. once daily; * treatment with continuous veno-venous hemodiafiltration. exclusion criteria: * indications for low molecular weight heparin use other than anticoagulant prophylaxis; * intracranial hemorrhage; * incident of serious bleeding within a week before admission to icu, if not managed; * disseminated intravascular coagulopathy; * heparin induced thrombocytopenia; * hypersensitivity or allergic reaction to enoxaparin or fondaparinux; * thrombocytopenia \< 50 g/l; * prothrombin time \ 1.7; * use of antiplatelet drugs; * presence of congenital coagulopathy.

Keywords: continuous veno-venous hemodiafiltration enoxaparin low molecular weight heparin lmwh cvvhdf anticoagulant prophylaxis critically ill fondaparinux anti-xa activity
comparative assessment of mental/incisive and inferior alveolar nerve block anesthesia in root canal treatment of mandibular premolars

Conditions: Mandibular Nerve; Mandibular Nerve Blocks; Premolars; Mental Nerve Block

Summary: the goal of this clinical trial is to systematically compare the pain scores and anesthesia efficacy of ianb and mnb in the treatment of symptomatic mandibular first and second premolars. this study aims to address gaps in current evidence and clarify whether these anesthesia techniques differ in effectiveness and patient experience during endodontic procedures. the hypotheses include: (i) no difference in pain perception between ianb and mnb, (ii) no difference between first and second premolars with ianb, and (iii) no difference between first and second premolars with mnb.


Eligibility criteria:
inclusion criteria: * individuals classified as asa 1 or asa 2. * age range of 18 to 65 years. * no known allergies to articaine or epinephrine. * absence of facial paresthesia. * no use of analgesic medications within 6 hours prior to treatment. * no use of medications, such as tricyclic antidepressants or beta blockers, that may interfere with anesthesia. * no pathological conditions at the planned injection site. * periodontal pocket depth of 3 mm or less. * mandibular first or second premolars diagnosed with symptomatic irreversible pulpitis. * teeth meeting glickman's gingival health criteria upon periodontal examination. * radiographically closed root apex with no detectable pathology. * patients must be literate and able to comprehend the use of a pain scale to provide informed consent voluntarily. exclusion criteria: * presence of systemic conditions contraindicating endodontic treatment. age below 18 or above 65 years. * pregnancy. * documented allergy to articaine with 1:100,000 epinephrine. * evidence of periapical pathology or radiolucency observed in radiographs. * recent use of central nervous system depressants or analgesic medication within 6 hours prior to treatment. * absence of reported lip numbness 10 minutes following ianb or minb injection. presence of a large restoration on the affected tooth.

Keywords: inferior alveolar nerve block local anesthesia mental nerve block pain premolar
a four-week clinical trial investigating efficacy and safety of cannabidiol as a treatment for acutely ill schizophrenic patients

Conditions: Schizophrenia

Summary: schizophrenia is a heterogeneous mental disorder that affects one percent of the world's population. current antipsychotics are only partially effective, and their use is often associated with serious side effects. cannabidiol is a natural counterpart of the psychoactive component of marijuana, delta-9-tetrahydrocannabinol. while cannabidiol has no psychotomimetic or addictive properties, it indirectly affects endogenous cannabinoid signalling by impairing the degradation of the endocannabinoid anandamide. in a controlled clinical trial of cannabidiol versus amisulpride (an established antipsychotic) in acute paranoid schizophrenics the investigators showed a significant clinical improvement in all symptoms of schizophrenia compared to baseline with either treatment. but cannabidiol displayed a significantly superior side-effect profile. this study is to evaluate the efficacy and safety of this novel treatment option in comparison to placebo and olanzapine, an established second generation antipsychotic in the treatment of acute schizophrenia and schizophrenia maintenance therapy, in a four-week clinical trial.


Eligibility criteria:
inclusion criteria: * informed consent given by the subject * dsm-iv-tr diagnosis of schizophrenic psychosis (295.10, 295.20, 295.30, 295.90 (american psychiatric association) * patients must be within the first three years of illness, i.e. first diagnosis of schizophrenia is no older than three years. * age 18 to 65 years, male or female * minimal initial panss score of 75 at baseline * female patients of childbearing potential need to utilize a proper method of contraception. * body mass index between 18 and 40 exclusion criteria: * lack of accountability (assessed by an independent psychiatrist) * history of treatment-resistant schizophrenia, defined as no response to at least two antipsychotics given for a minimum of 6 weeks each in an adequate dosage * positive urine drug-screening for illicit drugs at screening (except cannabinoids and benzodiazepines) * serious suicidal risk at screening visit (subject to investigator's and independent psychiatrist's judgement: poses a serious suicidal or homicidal risk at screening visit or has made a serious suicide attempt within the last 12 months prior to screening visit, or has exhibited homicidal behaviour at anytime during her/his lifetime) * known intolerance or allergy to olanzapine or cannabidiol * other relevant interferences of axis 1 (e.g. serious depression) according to diagnostic evaluation (mini) including residual forms of schizophrenia * pregnancy, as determined through a β-hcg pregnancy test, or lactation
analysis of circulating tumor dna dynamics to predict and monitor response to tki in patients with advanced nsclc.

Conditions: Non Small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IIIC Non-Small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer; Tyrosine Kinase Inhibitors

Summary: this is an observational study, aiming to investigate whether the ctdna dynamics analyzed by the k-tracktm assay could predict early response to tyrosine kinase inhibitors (tkis) in patients with advanced non-small cell lung cancer (nsclc). 1. determine relationship between ctdna dynamics and clinical response to tki, * no response/progressive disease = ctdna levels increase from baseline * partial response/stable disease = ctdna levels decrease from baseline * complete response = ctdna clearance. 2. compare and combine ctdna dynamics and recist1.1 to predict clinical response. 3. determine relationship between ctdna dynamics and progression free survival, overall survival.

this study is recruiting female and male patients, aged 18 and older: * who are diagnosed with advanced non-small cell lung cancer and indicated for tki (first or second line). tki combined with chemotherapy is allowed, * who have not started tki / chemotherapy before enrollment, * who have no medical or psychiatric conditions or occupational responsibilities that may preclude compliance with the protocol, * ffpe/fna sample is available, * compliant with treatment protocol, * patients consented to participate in the study. as part of the protocol, demographic data, medical and family history, and any relevant prior concomitant medication data will be recorded during follow-up visits. all patients are to be followed for 2 years from enrollment, with ct scan imaging measured every clinical visit for 24 months. sample collection: * 10 ml of peripheral blood (in streck tubes) is collected for ctdna analysis at 8 time points: pre-treatment (\<10 days before tki), during tki every 3 months until 21 months. * 6-8 sections of formalin-fixed paraffin-embedded (ffpe) tumor samples before tki/chemotherapy treatment.

Eligibility criteria:
inclusion criteria: * patients are diagnosed with advanced non-small cell lung cancer and indicated for tki (first or second line). tki combined with chemotherapy is allowed. * ffpe/fna sample is available. * compliant with treatment protocol. * patients consented to participate in the study. exclusion criteria: * patients already started tki before enrollment. * patients already started chemotherapy before enrollment. * medical or psychiatric conditions or occupational responsibilities that may preclude compliance with the protocol. * patients did not agree to participate in the studies.

Keywords: liquid biopsy circulating tumour dna vietnam